CN104725350A - Polycrystalline B-type crystal of alogliptin hydrochloride, preparation method and production purpose thereof - Google Patents
Polycrystalline B-type crystal of alogliptin hydrochloride, preparation method and production purpose thereof Download PDFInfo
- Publication number
- CN104725350A CN104725350A CN201310717030.XA CN201310717030A CN104725350A CN 104725350 A CN104725350 A CN 104725350A CN 201310717030 A CN201310717030 A CN 201310717030A CN 104725350 A CN104725350 A CN 104725350A
- Authority
- CN
- China
- Prior art keywords
- degrees
- crystal
- polycrystalline type
- hydrochloride
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 239000013078 crystal Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 title abstract description 10
- 229960001667 alogliptin Drugs 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 9
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 3
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000006471 dimerization reaction Methods 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001291 vacuum drying Methods 0.000 claims description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000004682 monohydrates Chemical class 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- XDFORSMZCYHNBG-UHFFFAOYSA-N benzonitrile;hydrochloride Chemical compound Cl.N#CC1=CC=CC=C1 XDFORSMZCYHNBG-UHFFFAOYSA-N 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- 239000006227 byproduct Substances 0.000 abstract description 18
- 238000006243 chemical reaction Methods 0.000 abstract description 14
- 239000000539 dimer Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 229960000935 dehydrated alcohol Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012452 mother liquor Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- 238000000967 suction filtration Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000009413 insulation Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- GGPNYXIOFZLNKW-ZJIMSODOSA-N (3r)-piperidin-3-amine;dihydrochloride Chemical compound Cl.Cl.N[C@@H]1CCCNC1 GGPNYXIOFZLNKW-ZJIMSODOSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000447 alogliptin benzoate Drugs 0.000 description 1
- KEJICOXJTRHYAK-XFULWGLBSA-N alogliptin benzoate Chemical compound OC(=O)C1=CC=CC=C1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 KEJICOXJTRHYAK-XFULWGLBSA-N 0.000 description 1
- 230000005260 alpha ray Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013070 direct material Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a polycrystalline B-type crystal of alogliptin hydrochloride and a preparation method thereof. The polycrystalline B-type crystal is prepared by an x-ray powder diffraction method of Cu-K alpha radiation, and the x-ray powder diffraction comprises peaks with 2 theta being 8.87+/-0.2 degrees, 12.67+/-0.2 degrees, 14.39+/-0.2 degrees, 14.84+/-0.2 degrees, 16.33+/-0.2 degrees, 18.66+/-0.2 degrees, 19.12+/-0.2 degrees, 20.20+/-0.2 degrees, 22.49+/-0.2 degrees, 24.18+/-0.2 degrees, 24.54+/-0.2 degrees, 25.48+/-0.2 degrees, 27.31+/-0.2 degrees, 28.83+/-0.2 degrees, 30.18+/-0.2 degrees, 32.97+/-0.2 degrees, 36.85+/-0.2 degrees and 38.76+/-0.2 degrees. The high-purity crystal obtained can be precipitated out of a system, a dimer by-product in the reaction can be effectively removed, production efficiency is raised, and production cost is reduced.
Description
Technical field
The present invention relates to the crystal of medical compounds, particularly, the present invention relates to the polycrystalline Type B of Egelieting hydrochloride, its preparation method and production purposes.
Background technology
SYR-322 (Alogliptin benzoate) is serine protease DPP IV (DPP-IV) inhibitor of Japanese Takeda company research and development, the level of glucagon-like peptide 1 in body (GLP-1) and glucose-dependent-insulinotropic polypeptide (GIP) can be maintained, promote the secretion of Regular Insulin, thus play hypoglycemic curative effect.Obtain the listing approval of Japanese MHLW in April, 2010.Chemical structure is as follows:
Molecular formula: C
18h
21n
5o
2c
7h
6o
2molecular weight: 461.51.Egelieting chemical name: 2-[[6-[(3R)-3-amino-piperidino]-3,4-dihydro-3-methyl-2,4-dioxo-1 (2H)-pyrimidyl] methyl] cyanobenzene.
Significantly suppress DPP-4 Alogliptin high selectivity, good for diabetes B patient tolerance, without dose-limiting toxicity, drug accumulation phenomenon is there is not when multiple dose administration, the full patient of Liver and kidney function also without the need to adjust dosage and Pharmacokinetic Results also the impact of unable to take food thing also do not find that severely adverse event and dead case do not have patient to drop by the wayside in the untoward reaction found because of untoward reaction yet under study for action, modal is headache, also has constipation and hypoglycemia in addition.
Therefore the SYR-322 production technique that exploitation one is good, can reduce cost greatly, reduces the price of streat drug, can bring more welfare to diabetic.
Egelieting hydrochloride is as the intermediate of in production technique, according to prior art, such as international monopoly WO2007035629, Egelieting is preferably by 2-(the chloro-3-methyl-2 of 6-, 4-dioxo-3,4-dihydro-2-H-pyrimidine-1-ylmethyl) be separated with additive salt after the synthetic method that starts of cyanobenzene and (R)-3-amino piperidine dihydrochloride, be such as separated with hydrochloride, benzoate, trifluoroacetate or tosylate.Described preparation method causes the dimerization by product producing general formula (A) usually, and it is difficult to remove from target product:
Chinese patent CN102942556 then adopts expensive N-Boc-3-amido piperidine hydrochlorate or N-Boc-3-amino piperidine raw material to replace upper patent material (R)-3-amino piperidine dihydrochloride to avoid producing in technique the dimerization by product of general formula (A), and therefore cost has uprised greatly.
Therefore need to produce 2-[6-[3 (R)-amino piperidine-1-base]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-1-ylmethyl] the improving one's methods of cyanobenzene acid salt, especially effectively remove the dimerization by product of general formula (A) and be applicable to carrying out with low cost the method for scale operation simultaneously.
The dimerization by product of general formula (A) must not be more than 0.1% in the requirement of finished product SYR-322, so the amount controlling this impurity in intermediate is particularly important, it directly affects drug quality, if the amount of this impurity meets requirements for pharmaceuticals in intermediate, so just directly control quality risk.
Polymorphism refers to that element or compound form the phenomenon with the solid state of different physicochemical property with different crystal formations.Different polymorphs bodies is different in structures and characteristics.Various physical properties, as solubleness, density, stability, fusing point etc. all change with crystal formation difference.Medical solid forms molecular crystal usually, is easy to obtain polymorphous variant.Meanwhile, in drug research field, polymorphic further comprises the polycomponent such as organic solvate, hydrate crystalline form.The different physical and chemical performance of these different crystal forms or processability directly have influence on safety, the effective performance of medicine sometimes.Therefore the important research content that crystal formation is studied and control becomes in drug development process, it directly affects the final quality of medicine.
Summary of the invention
Another aspect provides the polycrystalline Type B of compound shown in formula I, described polycrystalline Type B uses the alpha-emitting XRPD(X-ray powder diffraction of Cu-K) spectrum as shown in Figure 4, wherein X-ray powder diffraction data are as following table:
| Diffraction angle 2 θ (°) | D-value (0.1nm) | Relative intensity (%) |
| 8.87 | 9.97 | 68.9 |
| 12.67 | 6.98 | 18.6 |
| 14.39 | 6.15 | 21.7 |
| 14.84 | 5.97 | 60.7 |
| 16.33 | 5.42 | 48.4 |
| 18.66 | 4.75 | 14 |
| 19.12 | 4.64 | 100 |
| 20.20 | 4.39 | 12.8 |
| 22.49 | 3.95 | 70.8 |
| 24.18 | 3.68 | 52.9 |
| 24.54 | 3.63 | 17 |
| 25.48 | 3.49 | 66.1 |
| 27.31 | 3.26 | 25.8 |
| 28.83 | 3.09 | 38.8 |
| 30.18 | 2.96 | 15.5 |
| 32.97 | 2.71 | 12.7 |
| 36.85 | 2.44 | 12.7 |
| 38.76 | 2.32 | 10.6 |
The IR(infrared absorption of described polycrystalline Type B) spectrum as shown in Figure 5,3057,2941,2829,2222,1698,1614,1577,1533,1450,1366,1212,1120,845,770cm
-1there is absorption peak at place.
The DSC(means of differential scanning calorimetry of described polycrystalline Type B measures) collection of illustrative plates is as shown in Figure 6, wherein the initial value of endothermic transition temperature is at about 112.0 DEG C, thermogravimetic analysis (TGA) (TGA) data are 4.7% simultaneously, its water content detection result is 5.0%, the matter water-containing of 1 crystal water is 4.6% in theory, three's data are substantially identical, can judge that polycrystalline Type B is as monohydrate.
Thermal analyses (TGA and DSC) instrument and testing conditions information as follows:
INSTRUMENT MODEL: U.S. PerkinElmer Thermal Analysis differential thermal analyzer
Condition determination: temperature rise rate: 15 DEG C/min; Atmosphere: nitrogen;
X-ray diffractometer information is as follows:
INSTRUMENT MODEL: Japanese Rigaku Corporation D/max-γ A type diffractometer
Condition determination: Cu target K alpha-ray; Pipe pressure: 40KV; Guan Liu: 50mA; Slit: DS1 °, RS:0.15mm, SS:1 °.
The present invention relates to the preparation method of Egelieting hydrochloride crystal, wherein:
Described polycrystalline Type B is prepared as follows:
(1) Egelieting is dissolved in 1-10 volume alcoholic solvent;
(2), at stirring is cooled to-5 ~ 20 DEG C, 1 ~ 5 angelic acid is added;
(3)-5 ~ 20 DEG C of crystallizatioies;
(4) step (3) gained solid is 40 ~ 80 DEG C, vacuum-drying 6 ~ 8 hours under 0 ~ 10KPa condition;
Further, the alcoholic solvent described in method one step (1) is ethanol, methyl alcohol, propyl carbinol, Virahol or n-propyl alcohol or its mixture, is preferably ethanol;
Further, the alcoholic solvent consumption described in method one step (1) is 1 ~ 10 volume; Preferably 4 ~ 6 volumes;
Further, the acid described in method one step (1) is hydrochloric acid, acetic acid, phenylformic acid, oxalic acid or Hydrogen bromide, is preferably hydrochloric acid;
Further, the hydrochloric acid consumption described in method one step (2) is 1 ~ 5 equivalent, preferably 1 ~ 2 equivalent;
Further, the cooling conditions of method one step (2) is: cooling temperature at-5 ~ 20 DEG C, preferably 0 ~ 10 DEG C;
Further, the crystallization condition of method one step (3) is: recrystallization temperature at-5 ~ 20 DEG C, preferably 0 ~ 10 DEG C;
Further, with the sample obtained by the preparation method of polycrystalline Type B for raw material, the highly purified bulk drug SYR-322 that can prepare.
HPLC testing conditions:
Chromatographic column: Thermo BDS C8250 × 4.6mm5 μm, column temperature: 30 DEG C, determined wavelength: 278nm,
Flow velocity: 1.0ml/min, sample size: 10 μ l, working time: 30min,
The potassium dihydrogen phosphate (containing 0.3% triethylamine) of mobile phase A: 0.04mol/L, adjusts pH to 3.0 by strong phosphoric acid
Mobile phase B: acetonitrile
| Time(min) | A(%) | B(%) |
| 0 | 85 | 15 |
| 3 | 85 | 15 |
| 20 | 50 | 50 |
| 25 | 50 | 50 |
| 26 | 85 | 15 |
| 30 | 85 | 15 |
Working time: 30 minutes
Remarks: Fig. 8 is the dimerization by product reference substance HPLC of general formula (A), and appearance time is 19.5min, is purchased from TLC PHARMACHEM company outside this impurity.
Accompanying drawing explanation
Fig. 1 is the X-diffraction powder diffraction light spectrogram of the crystal (polycrystalline Type B) of embodiments of the invention 2;
Fig. 2 is the infrared spectrogram of the crystal (polycrystalline Type B) of embodiments of the invention 2;
Fig. 3 is Differential scanning calorimetry (DSC) figure and thermogravimetic analysis (TGA) (TGA) figure of the crystal (polycrystalline Type B) of embodiments of the invention 2;
Fig. 4 is that the filtrate HPLC of embodiments of the invention 1 detects collection of illustrative plates;
Fig. 5 is that the HPLC of the crystal (polycrystalline Type B) of embodiments of the invention 2 detects collection of illustrative plates;
Fig. 6 is that the HPLC of the SYR-322 of embodiments of the invention 8 detects collection of illustrative plates;
Fig. 7 is that the HPLC of the dimerization by product reference substance of general formula (A) detects collection of illustrative plates.
Embodiment
Be described below in detail embodiments of the invention, it should be noted that embodiment described below is exemplary, only for explaining the present invention, and can not limitation of the present invention be interpreted as.In addition, if do not clearly not stated, adopted in the following embodiments all reagent are, and market can be buied, or can according to text or the synthesis of known method, for the reaction conditions do not listed, be also that those skilled in the art easily obtain.
Prepared by embodiment 1 Egelieting reaction solution
400ml dehydrated alcohol is added in 1L tri-mouthfuls of reaction flasks, stir, then 80.5g2-(the chloro-3-methyl-2 of 6-is added, 4-dioxo-3,4-dihydro-2-H-pyrimidine-1-ylmethyl) cyanobenzene, (R)-3-amino piperidine dihydrochloride of 53.1g and 68.1g sodium carbonate, system is warming up to 75 DEG C of reactions, direct material has been reacted.
After having reacted, system is cooled to less than 40 DEG C, crosses and filter inorganic salt, use 80ml absolute ethanol washing filter cake 2 times respectively.Collect mother liquor (HPLC detected result is shown in accompanying drawing 4: have the dimerization by product per-cent 3.8%, 19.5min of general formula (A) to be the appearance time of the dimerization by product of general formula (A) in mother liquor) for subsequent use.
The polycrystalline Type B preparation of embodiment 2 Egelieting hydrochloride
By the mother liquor of 112ml embodiment 1, concentrated removal solvent, add 80.6ml anhydrous alcohol solution, transfer to 250ml three products reaction flask, magnetic agitation, system is cooled to 0 ~ 5 DEG C, drip 1.5 equivalent hydrochloric acid, temperature controls at 0-10 DEG C.Drip and finish, 0 ~ 10 DEG C of insulation 1h.Suction filtration, with 10ml dehydrated alcohol by filter cake washing twice, the polycrystalline Type B product 17.6g(HPLC detected result that 50 ~ 60 DEG C of vacuum-drying obtains Egelieting hydrochloride is shown in accompanying drawing 5: dimerization by product per-cent≤0.1% having general formula (A) in product, and 19.5min is the appearance time of the dimerization by product of general formula (A)).
The B crystal form preparation of embodiment 3 Egelieting hydrochloride
By the mother liquor of 56ml embodiment 1, concentrated removal solvent, add 40.3ml anhydrous alcohol solution, transfer to 100ml three products reaction flask, magnetic agitation, system is cooled to 0 ~ 5 DEG C, drip 1 equivalent hydrochloric acid, temperature controls at-5 ~ 0 DEG C.Drip and finish ,-5 ~ 0 DEG C of insulation 1h.Suction filtration, with 10ml dehydrated alcohol by filter cake washing twice, 50 ~ 60 DEG C of vacuum-dryings obtain the polycrystalline Type B product 8.7g(HPLC detected result of Egelieting hydrochloride: dimerization by product per-cent≤0.1% having general formula (A) in product).
The B crystal form preparation of embodiment 4 Egelieting hydrochloride
Get the mother liquor of 56ml embodiment 1, concentrated removal solvent, add 32.2ml dissolve with methanol, transfer to 100ml three products reaction flask, stir clearly molten, system is cooled to 0 ~ 5 DEG C, drip 2 equivalent hydrochloric acid, temperature keeps below 10 DEG C.Drip and finish, 0 ~ 10 DEG C of insulation 1h.Suction filtration, with 10ml dehydrated alcohol by filter cake washing twice, 70 ~ 80 DEG C of vacuum-dryings obtain the polycrystalline Type B product 6.5g(HPLC detected result of Egelieting hydrochloride: dimerization by product per-cent≤0.1% having general formula (A) in product).
The polycrystalline Type B preparation of embodiment 5 Egelieting hydrochloride
Get the mother liquor of 56ml embodiment 1, concentrated removal solvent, add 80.5ml anhydrous alcohol solution, transfer to 100ml three products reaction flask, stir clearly molten, system is cooled to 0 ~ 5 DEG C, drip 5 equivalent hydrochloric acid, temperature controls at 0 ~ 10 DEG C.Drip and finish, 10 ~ 20 DEG C of insulation 1h.Suction filtration, with 10ml dehydrated alcohol by filter cake washing twice, 40 ~ 50 DEG C of vacuum-dryings obtain the polycrystalline Type B product 8.5g(HPLC detected result of Egelieting hydrochloride: dimerization by product per-cent≤0.1% having general formula (A) in product).
The polycrystalline Type B preparation of embodiment 6 Egelieting hydrochloride
Get the mother liquor of 56ml embodiment 1, concentrated removal solvent, add 80.5ml Virahol and dissolve, transfer to 100ml three products reaction flask, stir clearly molten, system is cooled to 10 ~ 20 DEG C, drip 1.5 equivalent hydrochloric acid, temperature keeps below 10 ~ 20 DEG C.Drip and finish, 10 ~ 20 DEG C of insulation 1h.Suction filtration, with 10ml dehydrated alcohol by filter cake washing twice, 50 ~ 60 DEG C of vacuum-dryings obtain the polycrystalline Type B product 8.3g(HPLC detected result of Egelieting hydrochloride: dimerization by product per-cent≤0.1% having general formula (A) in product).
The polycrystalline Type B preparation of embodiment 7 Egelieting hydrochloride
Get the mother liquor of 56ml embodiment 1, concentrated removal solvent, add 80.5ml anhydrous alcohol solution, transfer to 100ml three products reaction flask, stir clearly molten, system is cooled to 0 ~ 5 DEG C, drip acetic acid 2 equivalent, temperature keeps below 10 DEG C.Drip and finish, 10 ~ 20 DEG C of insulation 1h.Suction filtration, with 10ml dehydrated alcohol by filter cake washing twice, 50 ~ 60 DEG C of vacuum-dryings obtain Egelieting acetate product 7.9g(HPLC detected result: dimerization by product per-cent≤0.1% having (B) in product).
Prepared by embodiment 8 SYR-322
The product 9.3g of Example 2 is added in 37.2g water and stirs, then adds 3.9g sodium carbonate, stirs clarification.Use 30ml dichloromethane extraction, separate methylene dichloride, concentrated removal methylene dichloride, adds 45ml dehydrated alcohol and 3.6g phenylformic acid, is warming up to 70-80 DEG C of reaction 3h.Be cooled to room temperature, suction filtration, obtain 9.9g white solid (HPLC detected result is shown in accompanying drawing 6: the appearance time having the dimerization by product per-cent of general formula (A) to be 0.01%, 19.5min to be the dimerization by product of general formula (A) in product).
Embodiment 9 stability experiment
For investigating the stable of the polycrystalline Type B of Egelieting hydrochloride, carried out Acceleration study to it and investigated, test-results is in table 1;
Egelieting hydrochloride prepared by Example 2, is placed on 40 DEG C/75%R.H. condition lower 30 days, investigates its stability, the results are shown in Table 1.
The method of concrete study on the stability can with reference to the method for Chinese Pharmacopoeia 2010 editions second annex XIX C; Purity detecting HPLC method, can with reference to the method for Chinese Pharmacopoeia 2010 editions second annex V D; The detection of crystal formation is with the method for embodiment.
The stability test of table 1 polycrystalline Type B
Above data show, moisture polycrystalline Type B is stored under normal temperature condition exists degraded risk, should store under cryogenic, or directly carry out lower step production in process of production, reduce period of storage to storage.
Although illustrate and describe embodiments of the invention above, be understandable that, above-described embodiment is exemplary, can not be interpreted as limitation of the present invention, those of ordinary skill in the art can change above-described embodiment within the scope of the invention when not departing from principle of the present invention and aim, revising, replacing and modification.
Claims (10)
1. an Egelieting hydrochloride polycrystalline Type B crystal, wherein said polycrystalline Type B crystal uses the alpha-emitting X-ray powder diffraction methods of Cu-K, it is 8.87 ° ± 0.2 ° that its X-ray powder diffraction comprises 2 θ, 12.67 ° ± 0.2 °, 14.39 ° ± 0.2 °, 14.84 ° ± 0.2 °, 16.33 ° ± 0.2 °, 18.66 ° ± 0.2 °, 19.12 ° ± 0.2 °, 20.20 ° ± 0.2 °, 22.49 ° ± 0.2 °, 24.18 ° ± 0.2 °, 24.54 ° ± 0.2 °, 25.48 ° ± 0.2 °, 27.31 ° ± 0.2 °, 28.83 ° ± 0.2 °, 30.18 ° ± 0.2 °, 32.97 ° ± 0.2 °, 36.85 ° ± 0.2 °, the peak of 38.76 ° ± 0.2 °.
2. according to polycrystalline Type B crystal according to claim 1, it is characterized in that: described polycrystalline Type B has powder x-ray diffraction figure as shown in Figure 1 substantially, it is 8.87 ° ± 0.2 ° that its X-ray powder diffraction comprises 2 θ, 12.67 ° ± 0.2 °, 14.37 ° ± 0.2 °, 14.84 ° ± 0.2 °, 16.33 ° ± 0.2 °, 18.66 ° ± 0.2 °, 19.12 ° ± 0.2 °, 20.20 ° ± 0.2 °, 22.49 ° ± 0.2 °, 24.18 ° ± 0.2 °, 24.54 ° ± 0.2 °, 25.48 ° ± 0.2 °, 27.31 ° ± 0.2 °, 28.83 ° ± 0.2 °, 30.18 ° ± 0.2 °, 32.97 ° ± 0.2 °, 36.85 ° ± 0.2 °, the peak of 38.76 ° ± 0.2 °.
3. Egelieting hydrochloride crystal according to claim 1 and 2, is characterized in that:
Described polycrystalline Type B has infrared spectra as shown in Figure 2,3057,2941,2829,2222,1698,1614,1577,1533,1450,1366,1212,1120,845, there is absorption peak at 770cm-1 place;
Described polycrystalline Type B has DSC(TGA as shown in Figure 3) collection of illustrative plates, the initial value of endothermic transition temperature is at about 112.0 DEG C, and thermogravimetic analysis (TGA) (TGA) data are 4.7% simultaneously, and its water content detection result is 5.0%.
4. polycrystalline Type B crystal according to claim 1 and 2, wherein said Type B crystal is monohydrate.
5. the preparation method of the polycrystalline Type B crystalline substance according to any one of claim 1-4, wherein,
Described polycrystalline Type B crystal is prepared as follows:
(1) Egelieting is dissolved in 1 ~ 10 volume alcoholic solvent;
(2) 1 ~ 5 angelic acid is added at stirring-5 ~ 20 DEG C;
(3)-5 ~ 20 DEG C of crystallizatioies;
(4) step (3) gained solid is 40 ~ 80 DEG C, vacuum-drying 6 ~ 8 hours under 0 ~ 10KPa condition.
6. preparation method according to claim 5, is characterized in that: the alcoholic solvent described in step (1) is ethanol, methyl alcohol, propyl carbinol, Virahol or n-propyl alcohol or its mixture, is preferably ethanol; Alcoholic solvent consumption described in step (1) is 1 ~ 10 times of volume, preferred 4-6 times volume.
7. preparation method according to claim 5, is characterized in that: the acid described in step (2) is hydrochloric acid, acetic acid, phenylformic acid, oxalic acid or Hydrogen bromide, is preferably hydrochloric acid.
8. preparation method according to claim 7, is characterized in that: described hydrochloric acid consumption is 1 ~ 5 equivalent, preferably 1 ~ 2 equivalent.
9. preparation method according to claim 5, is characterized in that: the cooling temperature of step (2) at-5 ~ 20 DEG C, preferably 0 ~ 10 DEG C; The recrystallization temperature of step (3) at-5 ~ 20 DEG C, preferably 0 ~ 10 DEG C.
10. manufacturing 2-[6-[3 (R)-amino piperidine-1-base]-3-methyl-2 containing the dimerization impurity being less than 0.1% general formula (A) according to the Egelieting hydrochloride of claim 1 crystallization B form, 4-dioxo-1,2,3,4-tetrahydropyrimidine-1-ylmethyl] application in benzonitrile hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310717030.XA CN104725350A (en) | 2013-12-23 | 2013-12-23 | Polycrystalline B-type crystal of alogliptin hydrochloride, preparation method and production purpose thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310717030.XA CN104725350A (en) | 2013-12-23 | 2013-12-23 | Polycrystalline B-type crystal of alogliptin hydrochloride, preparation method and production purpose thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104725350A true CN104725350A (en) | 2015-06-24 |
Family
ID=53449831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310717030.XA Pending CN104725350A (en) | 2013-12-23 | 2013-12-23 | Polycrystalline B-type crystal of alogliptin hydrochloride, preparation method and production purpose thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104725350A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101360723A (en) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | Process for preparing pyrimidinedione derivatives |
| CN102127057A (en) * | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors |
| WO2013046229A1 (en) * | 2011-09-26 | 2013-04-04 | Hetero Research Foundation | Novel salts of alogliptin |
-
2013
- 2013-12-23 CN CN201310717030.XA patent/CN104725350A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102127057A (en) * | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors |
| CN101360723A (en) * | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | Process for preparing pyrimidinedione derivatives |
| WO2013046229A1 (en) * | 2011-09-26 | 2013-04-04 | Hetero Research Foundation | Novel salts of alogliptin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2905973T3 (en) | Process for the preparation of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine dihydrochloride -2,4-diamine | |
| US20100016590A1 (en) | Nilotinib intermediates and preparation thereof | |
| JP6471103B2 (en) | Benzimidazol-2-ylpyrimidine modulator of histamine H4 receptor | |
| EP3626241B1 (en) | Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof | |
| EP2755959B1 (en) | Rilpivirine hydrochloride | |
| JP6602902B2 (en) | 2-(2-Aminocyclohexyl)aminopyrimidine-5-carboxamides as Spleen Tyrosine Kinase I (SYK) Inhibitors | |
| US11299477B2 (en) | Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof | |
| CN105524044A (en) | Trelagliptin impurity and its composition | |
| CN103601645B (en) | The preparation method of 1-(phenethyl amino) propane-2-alcohol compound or its salt | |
| KR20180099635A (en) | Oxalate salts of tenerigliptin and solvates, intermediates, processes for their preparation and markers | |
| US10017472B2 (en) | Hydrate of 2-isopropoxy-5-methyl-4-(piperidin-4-yl) aniline dihydrochloride, preparation method and use of the same | |
| CN104725349A (en) | Polycrystalline A-type crystal of alogliptin polycrystalline, preparation method and production purpose thereof | |
| CN105130996A (en) | 1,5-naphthalenedisulfonate and crystal form of benzodiazepine derivative and preparation methods of 1,5-naphthalenedisulfonate and crystal form | |
| CN109153652A (en) | The preparation process of 1- (aryl methyl) quinazoline -2,4 (1H, 3H)-diketone | |
| CN102633779B (en) | Fasudil acetate as well as preparation method and application thereof | |
| CN104725350A (en) | Polycrystalline B-type crystal of alogliptin hydrochloride, preparation method and production purpose thereof | |
| CN106588786A (en) | Preparation method of high purity favipiravir impurity | |
| EP3753940B1 (en) | Benzodiazepine derivative hydrochloride and crystal form, preparation method, and application thereof | |
| CN108586450B (en) | Recrystallization purification method of choline M receptor anticaking agent | |
| WO2023122868A1 (en) | Posaconazole impurity reference substance and preparation method therefor | |
| US20220162185A1 (en) | Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof | |
| TWI707851B (en) | Novel crystals of piperazine compounds | |
| EP3677581A1 (en) | Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof | |
| WO2011145548A1 (en) | Crystals of di(arylamino)aryl compound | |
| CN110483520B (en) | Crystal form of Bruton's tyrosine kinase inhibitor, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |